Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Recruiting
Trial end date:
2024-04-03
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well pembrolizumab and carboplatin work in treating
patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back
(recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Chemotherapy drugs, such as carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving pembrolizumab together with carboplatin may work better
in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Cancer Institute (NCI) United States Department of Defense